Richard Pesikoff
Psychiatry · Houston, TXNPI 1912950965
Payments from drug & device makers
Across 582 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Tris Pharma Inc$1K
- Supernus Pharmaceuticals, Inc.$848
- Lundbeck LLC$838
- plus $5K from 27 others
What the payments were for
- Food & beverage$11,750100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,756 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 13 | $33,230 |
| VyvanseLisdexamfetamine Dimesylate | 37 | $13,957 |
| TrintellixVortioxetine Hydrobromide | 14 | $8,899 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 254 | $6,794 |
| XanaxAlprazolam | 13 | $6,021 |
| Ziprasidone Hcl | 27 | $5,683 |
| Bupropion XlBupropion Hcl | 185 | $5,635 |
| Lisdexamfetamine Dimesylate | 23 | $5,131 |
| Alprazolam | 433 | $4,000 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 66 | $3,970 |
| Aripiprazole | 70 | $3,602 |
| Duloxetine Hcl | 111 | $3,026 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 36 | $2,541 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 17 | $2,177 |
| Lamotrigine | 123 | $2,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,860 | $33,23013 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $1,012 | $22,85751 claims |
| Almatica Pharma LLCSertraline Hcl | $16 | $1,08480 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$3M
- Lawrence GinsbergHouston$2.4M
- Asim ShahHouston$2.2M
- Aqeel HashmiHouston$1.3M
- Robert EarleHouston$1.1M
- Frank ChenHouston$941K
- Joao de QuevedoHouston$890K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.